WEDNESDAY, July 19, 2023 (HealthDay News) -- For patients with preclinical Alzheimer disease, solanezumab does not slow cognitive decline, according to a study published online July 17 in the New England Journal of Medicine to coincide with the annual Alzheimer's Association International Conference, held from July 16 to 20 in Amsterdam. Reisa A. Sperling, M.D.,